Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ALKS NASDAQ:AXSM NASDAQ:BPMC NASDAQ:GMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$42.65+0.8%$38.51$23.42▼$62.58$2.46B0.83550,194 shs508,961 shsALKSAlkermes$30.98+2.4%$29.22$25.17▼$36.45$5.00B0.541.83 million shs1.65 million shsAXSMAxsome Therapeutics$131.60+2.9%$119.49$75.56▼$139.13$6.38B0.52439,760 shs814,360 shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AGMABGenmab A/S$30.54-7.9%$28.14$17.24▼$33.65$21.30B0.982.59 million shs4.71 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.76%+4.23%+13.13%+7.54%-6.26%ALKSAlkermes+2.38%-3.70%+11.48%+14.61%+9.59%AXSMAxsome Therapeutics+2.86%+8.63%+13.50%+28.33%+40.97%BPMCBlueprint Medicines0.00%0.00%0.00%0.00%+50.53%GMABGenmab A/S-7.93%-6.55%+7.99%+40.09%+32.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$42.65+0.8%$38.51$23.42▼$62.58$2.46B0.83550,194 shs508,961 shsALKSAlkermes$30.98+2.4%$29.22$25.17▼$36.45$5.00B0.541.83 million shs1.65 million shsAXSMAxsome Therapeutics$131.60+2.9%$119.49$75.56▼$139.13$6.38B0.52439,760 shs814,360 shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AGMABGenmab A/S$30.54-7.9%$28.14$17.24▼$33.65$21.30B0.982.59 million shs4.71 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.76%+4.23%+13.13%+7.54%-6.26%ALKSAlkermes+2.38%-3.70%+11.48%+14.61%+9.59%AXSMAxsome Therapeutics+2.86%+8.63%+13.50%+28.33%+40.97%BPMCBlueprint Medicines0.00%0.00%0.00%0.00%+50.53%GMABGenmab A/S-7.93%-6.55%+7.99%+40.09%+32.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.57Moderate Buy$57.2534.23% UpsideALKSAlkermes 2.93Moderate Buy$42.0035.57% UpsideAXSMAxsome Therapeutics 3.00Buy$178.2035.41% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideGMABGenmab A/S 2.82Moderate Buy$40.8033.60% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, BPMC, GMAB, AGIO, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$191.00 ➝ $194.0010/15/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.0010/14/2025ALKSAlkermesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025AGIOAgios PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GMABGenmab A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/6/2025AGIOAgios PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/2/2025GMABGenmab A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/2/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $40.0010/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M67.89N/AN/A$27.02 per share1.58ALKSAlkermes$1.51B3.40$2.72 per share11.41$9.05 per share3.42AXSMAxsome Therapeutics$385.69M17.03N/AN/A$1.18 per share111.53BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54GMABGenmab A/S$3.12B6.28$1.40 per share21.88$8.04 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.88N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ALKSAlkermes$367.07M$2.0814.8922.611.6323.15%24.86%17.14%10/23/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.07N/A46.67N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)GMABGenmab A/S$1.14B$1.9915.3517.161.8537.53%21.03%16.98%11/6/2025 (Estimated)Latest ALKS, BPMC, GMAB, AGIO, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GMABGenmab A/S$0.47N/AN/AN/A$975.40 millionN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A10/30/2025Q3 2025AGIOAgios Pharmaceuticals-$1.94N/AN/AN/A$10.49 millionN/A10/23/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ALKSAlkermesN/A3.232.85AXSMAxsome Therapeutics1.661.571.51BPMCBlueprint Medicines1.012.802.75GMABGenmab A/SN/A6.226.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AALKSAlkermes95.21%AXSMAxsome Therapeutics81.49%BPMCBlueprint MedicinesN/AGMABGenmab A/S7.07%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ALKSAlkermes4.40%AXSMAxsome Therapeutics22.40%BPMCBlueprint Medicines4.21%GMABGenmab A/S1.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableGMABGenmab A/S2,682642.06 million632.18 millionOptionableALKS, BPMC, GMAB, AGIO, and AXSM HeadlinesRecent News About These CompaniesGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?October 20 at 4:16 PM | marketbeat.comGenmab shares drop over 3% on J&J’s amivantamab head and neck cancer dataOctober 20 at 9:16 AM | za.investing.comVanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMABOctober 19 at 3:34 AM | marketbeat.comWhat is HC Wainwright's Estimate for Genmab A/S Q2 Earnings?October 19 at 2:57 AM | americanbankingnews.comGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOctober 18 at 6:00 AM | globenewswire.comGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOctober 18 at 6:00 AM | businesswire.comWall Street Zen Downgrades Genmab A/S (NASDAQ:GMAB) to BuyOctober 18 at 2:42 AM | marketbeat.comWhat is HC Wainwright's Forecast for Genmab A/S Q3 Earnings?October 18 at 2:39 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next?October 17, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of Genmab A/S Q2 EarningsOctober 17, 2025 | marketbeat.comFY2026 EPS Estimates for Genmab A/S Cut by Leerink PartnrsOctober 17, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?October 16, 2025 | marketbeat.comUS Bancorp DE Has $1.82 Million Stock Holdings in Genmab A/S Sponsored ADR $GMABOctober 16, 2025 | marketbeat.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 16, 2025 | americanbankingnews.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 16, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC WainwrightOctober 15, 2025 | marketbeat.comLeerink Partnrs Reduces Earnings Estimates for Genmab A/SOctober 15, 2025 | marketbeat.comGMAB or TECH: Which Is the Better Value Stock Right Now?October 14, 2025 | zacks.comQ3 EPS Estimates for Genmab A/S Lowered by Leerink PartnrsOctober 14, 2025 | marketbeat.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025October 14, 2025 | globenewswire.com31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLCOctober 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Why the Precious Metal Nobody Talks About Could Be Your Best BetBy Jordan Chussler | October 4, 2025ALKS, BPMC, GMAB, AGIO, and AXSM Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$42.65 +0.32 (+0.76%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$42.39 -0.26 (-0.61%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Alkermes NASDAQ:ALKS$30.98 +0.72 (+2.38%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$31.57 +0.59 (+1.90%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Axsome Therapeutics NASDAQ:AXSM$131.60 +3.66 (+2.86%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$132.00 +0.40 (+0.30%) As of 10/20/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Blueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Genmab A/S NASDAQ:GMAB$30.54 -2.63 (-7.93%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$29.50 -1.04 (-3.41%) As of 05:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
